HIGHLIGHTS
- who: A. González del Alba from the The University of North Carolina group reported a clas- have published the paper: SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018), in the Journal: (JOURNAL)
- what: The aim of this Article is to provide recommendations about the management of muscle-invasive (MIBC) and metastatic bladder cancer. The study showed that the median duration of response (mDOR), a secondary endpoint, for those receiving atezolizumab was 21.7 months (95% CI 13.0, 21.7) in the overall study population, compared to 7 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.